Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Imunon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

R&D DAY SHOWCASED REMARKABLE INVESTIGATOR OPTIMISM, CONTINUED STRENGTHENING SUPPORTIVE DATA, AND SIGNIFICANT PROGRESS WITH PHASE 3 OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

IMUNON REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WEBCAST RECORDING AND SYMPOSIUM SLIDES NOW AVAILABLE LAWRENCEVILLE, N.J., NOV. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY HOSTED A COMPELLING PUBLIC WEBCAST, WHERE CANCER KEY OPINION LEADERS, PRINCIPAL INVESTIGATORS FROM THE PHASE 3 OVATION 3 AND PHASE 2 MINIMAL RESIDUAL DISEASE (MRD) TRIALS, CLINICIANS, STATISTICAL EXPERTS AND IMUNON EXECUTIVES SHARED CRITICAL INSIGHTS INTO THE DISEASE AND TRANSLATIONAL DATA, ALONG WITH COMPELLING CLINICAL DATA HIGHLIGHTING THE SIGNIFICANT POTENTIAL OF IMNN-001 FOR WOMEN WITH ADVANCED OVARIAN CANCER.

IMUNON PUBLIC WEBCAST HIGHLIGHTS RESILIENCE AND INNOVATION IN PURSUIT OF THE FIRST APPROVED IMMUNOTHERAPY FOR OVARIAN CANCER

EVENT BEING HELD TODAY AT 8:00 A.M. ET IN NEW YORK CITY FEATURES PRESENTATIONS FROM OVARIAN CANCER KEY OPINION LEADERS, CLINICIANS, STATISTICAL EXPERTS, AND IMUNON EXECUTIVES INVESTORS, STAKEHOLDERS, ANALYSTS AND THOSE INTERESTED IN ADVANCES IN OVARIAN CANCER TREATMENT AND WOMEN'S HEALTH ARE ENCOURAGED TO ATTEND, EITHER IN-PERSON OR VIRTUALLY LAWRENCEVILLE, N.J.

IMUNON R&D DAY SHOWCASES CLINICAL PROGRESS OF ITS NOVEL IMMUNOTHERAPY, PHASE 3 TRIAL AND SIGNIFICANT POTENTIAL FOR WOMEN WITH OVARIAN CANCER

INVESTORS AND STAKEHOLDERS INVITED TO ATTEND IN PERSON IN NEW YORK CITY OR VIA LIVE WEBCAST ON MONDAY, NOVEMBER 10TH AT 8:00 A.M. ET

IMUNON R&D DAY: OPPORTUNITY TO HEAR CLINICAL TRIAL INVESTIGATORS DISCUSS SIGNIFICANT POTENTIAL OF IMNN-001 TO REDEFINE OVARIAN CANCER TREATMENT

LAWRENCEVILLE, N.J., NOV. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AT11:00 A.M.

IMUNON TO HOLD THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON THURSDAY, NOVEMBER 13, 2025

INVESTOR EVENT IN NEW YORK CITY TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001; OFFERING IN-PERSON OR VIRTUAL ATTENDANCE ON NOVEMBER 10, 2025

IMUNON ANNOUNCES WEBCAST OF IN-PERSON R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

TRIALS-IN-PROGRESS POSTER OF ONGOING PIVOTAL PHASE 3 TRIAL OF DNA-MEDIATED IMMUNOTHERAPY ACCEPTED AT BOTH IGCS AND ESMO CONGRESS 2025 LAWRENCEVILLE, N.J., OCT. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT HAS BEEN INVITED TO PRESENT A TRIALS-IN-PROGRESS ABSTRACT ON THE ONGOING PHASE 3 OVATION 3 CLINICAL TRIAL OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, AT THE 2025 ANNUAL GLOBAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS), BEING HELD NOVEMBER 5-7, 2025 IN CAPE TOWN, SOUTH AFRICA.

IMUNON TO PRESENT PHASE 3 OVATION 3 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER AT IGCS 2025 ANNUAL GLOBAL MEETING

IMNN-001 PROGRAM IS CURRENTLY ADVANCING ITS OVATION 3 PIVOTAL PHASE 3 TRIAL PER PLAN LAWRENCEVILLE, N.J., OCT. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT NEW TRANSLATIONAL DATA FROM THE PHASE 2 OVATION 2 CLINICAL TRIAL OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, WILL BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, BEING HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

IMUNON TO PRESENT NEW TRANSLATIONAL DATA FROM PHASE 2 OVATION 2 STUDY OF IMNN-001 AT SITC 40TH ANNUAL MEETING

INVESTOR EVENT TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001 TO BE HELD IN NEW YORK CITY ON NOVEMBER 10, 2025 PROGRAM WILL FEATURE PRESENTATIONS FROM OVARIAN CANCER THOUGHT LEADERS, PHASE 3 STUDY INVESTIGATORS, ONCOLOGY AND STATISTICAL EXPERTS LAWRENCEVILLE, N.J., OCT. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY FOR INVESTORS AT THE HARVARD CLUB (35 WEST 44TH STREET) IN NEW YORK CITY ON NOVEMBER 10, 2025, BEGINNING AT 8:00 A.M.

IMUNON HOSTS R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

COMPANY SEEKS STRATEGIC PARTNERS TO ADVANCE NOVEL PLACCINE TECHNOLOGY LAWRENCEVILLE, N.J., OCT. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY FOCUSED ON DEVELOPING NON-VIRAL DNA-MEDIATED IMMUNOTHERAPIES AND EVALUATING AN ADAPTATION OF THE PLATFORM'S POTENTIAL AS A NEXT-GENERATION VACCINE, TODAY ANNOUNCED THAT MEMBERS OF ITS LEADERSHIP TEAM WILL DELIVER ORAL PRESENTATIONS HIGHLIGHTING IMNN-101, ITS INVESTIGATIONAL DNA PLASMID VACCINE BASED ON THE COMPANY'S PROPRIETARY PLACCINE TECHNOLOGY PLATFORM, INCLUDING PROOF-OF-CONCEPT CLINICAL TRIAL RESULTS AT THE FOLLOWING UPCOMING VACCINE CONFERENCES: 5TH EDITION OF INTERNATIONAL VACCINES CONGRESS (IVC) KEYNOTE ORAL PRESENTATION TITLE: A PROMISING NOVEL APPROACH TO DNA VACCINES PRESENTING AUTHOR: KHURSHEED ANWER, PH.D.

Imunon, Inc.

IMNN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Imunon, Inc.

IMNN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMNN